Novel Treatment for Diastolic Heart Failure in Women

Inclusion Criteria: * Women who are 18 years of age or older. * Women with clinical heart failure for \> 2 months. * Women with left ventricular ejection fraction \> 50% within 2 months of screening. * Women with New York Heart Association class II or III heart failure symptoms. * Brain Natriuretic Peptide \> 62 pg/ml within 2 months of screening. * Patient on angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy for at least 1 month. * Blood Pressure no more than 150/95. * Patient able to walk more than 50 meters at the time of enrollment. * Signed informed consent. Exclusion Criteria: * Current treatment with spironolactone. * Severe hepatic impairment. * Creatinine \> 2.5 mg/dl * Potassium \> 5.0 mEq/L * Intolerance to spironolactone in the past. * Significant valvular heart disease, pericardial disease, or severe chronic lung disease with cor pulmonale. * Unstable angina or myocardial infarction within the past 4 weeks. * Severe peripheral vascular disease or other physical conditions that would limit the walking distance. * Pregnant or lactating females. * Participation in any other drug trial within 30 days prior to randomization. * Inability to provide informed consent.